Southern Suburbs Dermatology, Sydney, Australia.
J Am Acad Dermatol. 2012 Mar;66(3):486-93. doi: 10.1016/j.jaad.2010.12.038. Epub 2011 Nov 4.
Current topical agents for field therapy of actinic keratoses have single mechanisms of action and must be applied for weeks. Ingenol mebutate gel, a novel drug for field therapy of actinic keratoses, appears to have a dual mechanism of action: (1) rapid lesion necrosis and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Because of the rapid destruction of actinic keratosis lesions after application of ingenol mebutate gel, treatment is necessary for only 2 or 3 days. The subsequent immune-mediated response targets any residual dysplastic epidermal cells. This dual mechanism of action should provide efficacy equivalent to that of current topical agents with a substantially shorter treatment period.
目前用于光化性角化病的局部治疗的药物作用机制单一，必须应用数周。新型光化性角化病局部治疗药物 Ingenol 咪喹莫特凝胶似乎具有双重作用机制：（1）快速病变坏死；（2）特定的中性粒细胞介导的、抗体依赖性细胞毒性作用。由于 Ingenol 咪喹莫特凝胶应用后光化性角化病皮损迅速坏死，因此仅需治疗 2 或 3 天。随后的免疫介导反应针对任何残留的异型表皮细胞。这种双重作用机制应该可以提供与目前的局部药物相同的疗效，但治疗时间大大缩短。
